The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
June 23rd 2022Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.
Read More
Further Analysis Needed to Incorporate Liquid Biopsy in the Community Setting
February 23rd 2022This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.
Read More
Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study
February 18th 2022A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.
Read More
More Info Needed to Establish Utility of MRD, SFLC Levels as Biomarkers in MM
February 12th 2022This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.
Read More
Liquid Biopsy May Have Prognostic, Theranostic Benefits in PDAC
February 5th 2022Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.
Read More
Precision Treatment With TIL Shows Promise in Metastatic Breast Cancer
February 2nd 2022Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Read More
Point-of-Care Testing Has Potential to Expand the Reach of NGS for CRC
January 27th 2022This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).
Read More
MRD Continues to Reliably Predict Disease Progression in CRC
January 24th 2022In this poster presented at the 2022 ASCO Gastrointestinal Cancers Symposium, minimal residual disease (MRD) status as detected by postsurgery plasma cell-free DNA continued its strong track record of being a reliable predictor of disease progression in colorectal cancer (CRC).
Read More
Understanding Real-World Trends in MRD Testing as Part of MM Management
January 18th 2022An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.
Read More
MRD Kinetics Identify High-risk CLL in Study of Zanubrutinib, Venetoclax, Obinutuzumab
January 16th 2022An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.
Read More
Targeted Cancer Therapies Showing Promise in Treating Parenchymal Brain Metastases
January 10th 2022Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.
Read More
Ibrutinib/Venetoclax Bests Chlorambucil/Obinutuzumab for Treating CLL
December 26th 2021Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.
Read More
Precision Medicine Can Close Oncology Gaps—and Lead to “Doing Less”
December 20th 2021Physicians said it is in payers’ interest to use artificial intelligence to address social determinants of health, to cover tests, and to gather data. Doing so could let them stratify who needs certain screenings and diagnostic procedures and who doesn’t, which could lead to less consumption of health care.
Read More
Daratumumab-Led Quad Therapy Aids MRD Surveillance in MM
December 17th 2021Final results from the MASTER trial presented at this year’s 63rd Annual American Society of Hematology Annual Meeting and Exposition bear out the benefits of quadruplet therapy and using minimal residual disease (MRD) status among patients with newly diagnosed multiple myeloma (MM).
Read More
From Challenges Spring Opportunities for Progress in Daratumumab-Based Clinical Pathways
December 14th 2021An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.
Read More